. . " "@en . . . . . . . "(S)-medetomidine"@en . . . . . . "A mass balance study demonstrated that after nine days an average of 95% of the radioactivity, following intravenous administration of radiolabeled dexmedetomidine, was recovered in the urine and 4% in the feces. Fractionation of the radioactivity excreted in urine demonstrated that products of N-glucuronidation accounted for approximately 34% of the cumulative urinary excretion. The majority of metabolites are excreted in the urine."@en . " "@en . . "(+)-4-((S)-alpha,2,3-Trimethylbenzyl)imidazole"@en . "Dexmedetomidinum"@en . "MPV 1440"@en . . "An agonist of receptors, adrenergic alpha-2 that is used in veterinary medicine for its analgesic and sedative properties. It is the racemate of dexmedetomidine. [PubChem]"@en . "approved"@en . . "Humans and other mammals"@en . "2 hours"@en . . . "Dexm\u00E9d\u00E9tomidine"@en . "* 118 L"@en . . "(+)-medetomidine"@en . . "94%"@en . "113775-47-6"@en . . "Dexmedetomidin"@en . . "For sedation of initially intubated and mechanically ventilated patients during treatment in an intensive care setting, also used in pain relief; anxiety reduction and analgesia"@en . . "Dexmedetomidine"@en . . "Inese Reine, Armands Zandersons, \"METHOD FOR PREPARING MEDETOMIDINE AND ITS SALTS..\" U.S. Patent US20100048915, issued February 25, 2010."@en . . "Dexmedetomidina"@en . . . . . . . . . . . . . . . "* 39 L/h [Healthy volunteers receiving IV infusion (0.2-0.7 mcg/kg/hr)]"@en . . . . . . . . . "Dexmedetomidine is a specific and selective alpha-2 adrenoceptor agonist. By binding to the presynaptic alpha-2 adrenoceptors, it inhibits the release if norepinephrine, therefore, terminate the propagation of pain signals. Activation of the postsynaptic alpha-2 adrenoceptors inhibits the sympathetic activity decreases blood pressure and heart rate."@en . . . . . . .